{"id":"NCT04908722","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults","officialTitle":"A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-18","primaryCompletion":"2023-07-10","completion":"2023-07-10","firstPosted":"2021-06-01","resultsPosted":"2024-05-23","lastUpdate":"2025-02-04"},"enrollment":1609,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["COVID-19 Prevention"],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.COV2.S","otherNames":["JNJ-78436735","Ad26COVS1","VAC31518"]}],"arms":[{"label":"Group 1: Ad26.COV2.S Dose Level 1","type":"EXPERIMENTAL"},{"label":"Group 2: Ad26.COV2.S Dose Level 2","type":"EXPERIMENTAL"},{"label":"Group 3: Ad26.COV2.S Dose Level 3","type":"EXPERIMENTAL"},{"label":"Group 4: Ad26.COV2.S Dose Level 4","type":"EXPERIMENTAL"},{"label":"Group 5: Ad26.COV2.S Dose Level 5","type":"EXPERIMENTAL"},{"label":"Group 6: Ad26.COV2.S Dose Level 6","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.","primaryOutcome":{"measure":"Geometric Mean Concentration of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination","timeFrame":"28 days after first vaccination (at Day 29)","effectByArm":[{"arm":"Group 1: Ad26.COV2.S 9x10^10 vp","deltaMin":2351,"sd":null},{"arm":"Group 2: Ad26.COV2.S 7x10^10 vp","deltaMin":1714,"sd":null},{"arm":"Group 3: Ad26.COV2.S 5x10^10 vp","deltaMin":2189,"sd":null},{"arm":"Group 4: Ad26.COV2.S 3.5x10^10 vp","deltaMin":1377,"sd":null},{"arm":"Group 5: Ad26.COV2.S 2.5x10^10 vp","deltaMin":1626,"sd":null},{"arm":"Group 6: Ad26.COV2.S 1.25x10^10 vp","deltaMin":1976,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG002 vs OG004","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG005","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":43,"countries":["United States","Brazil","Germany","Poland","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":288},"commonTop":["Vaccination Site Pain(Solicited)","Headache(Solicited)","Fatigue(Solicited)","Myalgia(Solicited)","Nausea(Solicited)"]}}